IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Rodger, et al.		
	To be assigned BINATION THERAPY FOR TREATING CHRONIC AMMATORY DISEASES	Art Unit: _ Examiner:	
Commissione	r for Patents		

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

DATE OF DEPOSIT 12-21-2005	
EXPRESS MAR ID EV GGOGGIAS IN	\overline{z}
I HEREBY CERTIFY THAT THIS COMMEMONDERICE IS	
I REMEDIT COMMITTERS COMMITTERS CONTROL OF THE COMMITTERS CONTROL OF T	
BEING DEPOSITED WITH THE UNITED STATES POSTAL	
SERVICE AS EMPRESS MAIL "POST OFFICE TO	
ADDRESSEE" BEFORE & P.M. ON THE ABOVE DATE IN	
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER	ł
FOR PATENTS, WASHINGTON, D.C., 20231.	

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 28313-1450, on the date appearing below.

MERCK & CO., INC.

By _____ Date ____

RELATED APPLICATION

INFORMATION DISCLOSURE STATEMENT POTIFIC 21 DEC 2005

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
·		
		-
If this is inconvenient, additional copies will be submitted upon requ	iest.	
6. In accordance with 37 C.F.R. 1.97, (check one)		
the attached information is filed within three months of the filing	date of the captioned case.	
the attached information is filed more than three months after the Office Action on the merits.	ne filing date but prior to the	mailing of a first
the attached information is filed before the mailing of a first Office examination under §1.114.	ce action after the filing of a	request for continued
the attached information is being filed more than three months a Office Action on the merits, but before the mailing date of a Fina otherwise closes prosecution in the application. The enclosed a Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(al Action, Notice of Allowand authorization is therefore giv	e, or an action that
each item of information contained in this Information Disclosure from a foreign patent office in a counterpart foreign application statement.		
each item of information contained in the information disclosure from a foreign patent office in a counterpart application and this designated in §1.56(c) more than thirty days prior to the filing of	s communication was not red	ceived by any individual
no item of information contained in this Information Disclosure S foreign patent office in a counterpart foreign application, and, to after making reasonable inquiry, was known to any individual demonths prior to the filing of this Statement.	the knowledge of the perso	n signing the certification
	Respectfully submitted,	
	_	

By: Raynard Yuro

Attorney For Applicant(s)

Reg. No. 45,570

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-<u>0182</u>

Date: December 19, 2005

APZOS BESTFEITE for PTO/S BA98A (07-05), "Information Disclosure Statement by Applicant Program of Conference Office; II S DEPARTMENT OF COMMERCE

_					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE	
ş.	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN		
I	NFORMATION :	DIS	CLOSURE	Application Number	To be assigned R B A B D D	
	TATEMENT BY	A TO	DITCANIT	Filing Date		
3	IAIEWENI DI	AP	PLICANI	First Named Inventor	Rodger, et al.	
				Group Art Unit		
(use as many sheets as necessary)				Examiner Name		
Sheet	1	of	2	Attorney Docket Number	21411P	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY		
		2003/0157061		Dennis A. Bennett	08/21/2003		
		2003/0077297		Chen, et al.	04/24/2003		
ļ							
ļ							
	1						

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	0.55	Foreign Patent Documen	Kind	Name of Patentee or Applicant	Date of Publication of Cited Document	
Initials*	No.	Office	Number	Code (if known)	of Cited Document	MM-DD-YYYY	
			WO 03/016248		BRISTOL-MYERS SQUIBB COMPANY	02/27/2003 .	
			WO 03/002713		ABGENIX, INC.	01/09/2003	
			WO 01/37808		LIPOCINE, INC.	05/31/2001	
			WO 01/28555		LIPOCINE, INC.	04/26/2001	
			WO 01/00229		PHARMACIA CORPORATION	01/04/2001	
			EP 1 104 760 B1		PFIZER PRODUCTS INC.	03/12/2003	
			EP 1 104 760 A1		PFIZER PRODUCTS INC.	06/06/2001	
			WO 2005/004806		MERCK & CO. INC.	01/20/2005	

	Examiner Signature		Date Considered	
--	-----------------------	--	--------------------	--

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Sı	Substitute for form 1449B/PTO		COMPLETE IF KNOWN		
i	NFORMATION 1	DIS	CLOSURE	Application Number	To be 3 sens d 5 6 1 6 / 6
C	TATEMENT BY	A D	DI ICANIT	Filing Date	
	TATEMENT DI	АГ	FLICANI	First Named Inventor	Rodger, et al.
	(,	Group Art Unit	
	(use as many sheets	as n	ecessary)	Examiner Name	
Sheet	2	of	2	Attorney Docket Number	21411P

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
		El Desoky, et al., Database Biosis On Stn. Accession No. 2001:182368, Current Therapeutic Research, Vol., 61, No. 2, pp. 92-112, 2001					
		Saravanan, et al., Expert Opinion, "Advances in the Treatment of Rheumatoid Arthritis: Old Versus New Therapies", Vol. 3 No. 7, pp 845-856, 2002					
		Hocherl, et al., Journal of American Society of Nephrology, "Cyclosporine A Suppresses Cyclooxygenase-2 Expression in the Rat Kidney", Vol. 13, No. 10, pp. 2427-2436, 2002					
		Nurmohamed, et al, Drugs, "Cardiovascular Risk Profile of Antirheumatic Agents in Patients with Osteoarthritis and Rheumatoid Arthritis", Vol. 62, No. 11, pp. 1599-1609, 2002					
		Luong, et al, The Annals of Pharmacotherapy, "Treatment Options for Rheumatoid Arthritis: Celecoxib, Leflunomide, Etanercept, and Infliximab", Vol. 34 No. 6, pp. 743-760, 2000					
		Ehab S. El Desoky, MD, Current Therapeutic Research, "Pharmacotherapy of Rheumatoid Arthritis: An Overview", Vol. 62 No. 2, pp. 92-112, 2001					

Examiner	Data	
	Date	
Signature	Considered	
Olghataic	Considered	
		<u> </u>

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.